Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2025)

Tarsus Pharmaceuticals has reported Gross Margin over the past 5 years, most recently at 92.8% for Q4 2025.

  • Quarterly results put Gross Margin at 92.8% for Q4 2025, up 21.0% from a year ago — trailing twelve months through Dec 2025 was 93.2% (up 21.0% YoY), and the annual figure for FY2025 was 93.2%, up 21.0%.
  • Gross Margin for Q4 2025 was 92.8% at Tarsus Pharmaceuticals, roughly flat from 93.0% in the prior quarter.
  • Over the last five years, Gross Margin for TARS hit a ceiling of 107.1% in Q4 2021 and a floor of 79.85% in Q3 2023.
  • Median Gross Margin over the past 5 years was 93.9% (2025), compared with a mean of 94.29%.
  • Biggest five-year swings in Gross Margin: tumbled -1110bps in 2022 and later surged 1341bps in 2024.
  • Tarsus Pharmaceuticals' Gross Margin stood at 107.1% in 2021, then decreased by -10bps to 96.0% in 2022, then fell by -6bps to 90.7% in 2023, then grew by 2bps to 92.58% in 2024, then rose by 0bps to 92.8% in 2025.
  • The last three reported values for Gross Margin were 92.8% (Q4 2025), 93.0% (Q3 2025), and 93.92% (Q2 2025) per Business Quant data.